United Kingdom (UK)
Recombinant monoclonal antibody to IdeS-cleaved hinge of IgG1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma C2095.
Alternative Name(s) of Target: IdeS-cleaved hinge of IgG4
Immunogen: This antibody was raised by immunising rabbit with a KLH‐conjugated peptide (CTAPPAPAPELLG).
Specificity: C2095 targets the IdeS‐cleaved hinge of human IgG1, but not intact IgG1 or IgG1 cleaved by MMP-3 or GluV8. The antibody can also bind IdeS-cleaved hinge of human IgG4 but not IdeS-cleaved hinge of IgG2.
Application Notes: ELISA demonstrated C2095 has robust binding to IdeS-generated F(ab')2 fragments of human IgG1 and human IgG4 but does not bind IdeS-generated F(ab')2 fragments of human IgG2. It also does not bind the intact IgG1, IgG2 or IgG4 counterparts (Brezski et al, 2014). ADCC and CDC assays showed C2095 is capable of restoring antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against WIL2-S cells to the otherwise inactive anti-CD20 IgG1 F(ab’)2 fragment. It also reinstated ADCC against MDA-MB-231 cells to an anti-CD142 IgG1 F(ab’)2 fragment. This antibody was also capable of eliciting both CDC and ADCC to IgG4 F(ab’)2 fragments (Brezski et al, 2014).
Antibody first published in:
Brezski et al, 2014. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. MAbs. 2014;6(5):1265-73 PMID:25517311
Note on publication:
Describes the original generation of C2095 and its characterisation through ADCC and FCC assays.